ReviewFrontiers in endocrinology2023
Role of irisin in bone diseases.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors.Pharmacology & therapeutics · 2026Review
- Exercise-myokine relationships in osteoarthritis.Journal of translational medicine · 2026Review
- Developing Subcutaneous Formulations for Irisin as a Potential Therapeutic.Pharmaceutical research · 2025Article
- Trolox, r-irisin and resveratrol cocktail to counteract osteoblast metabolism alterations in osteoarthritis and osteoporosis.Journal of bone and mineral metabolism · 2025Article
- Sclerostin's role in bone-muscle crosstalk and osteoporosis pathogenesis.Osteoporosis and sarcopenia · 2025Review
- New perspectives on molecular mechanisms underlying exercise-induced benefits in Parkinson's disease.NPJ Parkinson's disease · 2025Review
- Irisin Concentrations in Children and Adolescent Cancer Survivors and Their Relation to Metabolic, Bone, and Reproductive Profile: A Pilot Case-Control Study.Journal of clinical medicine · 2025Article
- Fndc5/irisin mediates the benefits of aerobic exercise intervention on aging-associated sarcopenia in mice.European geriatric medicine · 2025Article
- Irisin mitigates osteoporotic-associated bone loss and gut dysbiosis in ovariectomized mice by modulating microbiota, metabolites, and intestinal barrier integrity.BMC musculoskeletal disorders · 2025Article
- Irisin and its role in fracture healing: A comparative study with hyaluronic acid and platelet-rich plasma in a rat model.Joint diseases and related surgery · 2025Article
- Comparison of passive and active motion: effect of myokine irisin on cartilage in knee osteoarthritis rats.Frontiers in physiology · 2025Article
- The protective effect of irisin against hemorrhagic injury is mediated by PI3K and p38 pathways in hemorrhage/resuscitation.The Journal of pharmacology and experimental therapeutics · 2025Article
- Immunocyte-derived extracellular vesicles in osteoimmunology: mechanisms, disease contexts, and translational prospects.Frontiers in immunology · 2025Review
- The Heterogeneity of Post-Menopausal Disease Risk: Could the Basis for Why Only Subsets of Females Are Affected Be Due to a Reversible Epigenetic Modification System Associated with Puberty, Menstrual Cycles, Pregnancy and Lactation, and, Ultimately, Menopause?International journal of molecular sciences · 2024Review
- The association of serum irisin with anthropometric, metabolic, and bone parameters in obese children and adolescents.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone diseases are common among middle-aged and elderly people, and harm to activities of daily living (ADL) and quality of life (QOL) for patients. It is crucial to search for key regulatory factors associated with the development of bone diseases and explore potential therapeutic targets for bone diseases. Irisin is a novel myokine that has been discovered in recent years. Accumulating evidence indicates that irisin has beneficial effects in the treatment of various diseases such as metabolic, cardiovascular and neurological disorders, especially bone-related diseases. Recent studies had shown that irisin plays the role in various bone diseases such as osteoarthritis, osteoporosis and other bone diseases, suggesting that irisin may be a potential molecule for the prevention and treatment of bone diseases. Therefore, in this review, by consulting the related domestic and international literature of irisin and bone diseases, we summarized the specific regulatory mechanisms of irisin in various bone diseases, and provided a systematic theoretical basis for its application in the diagnosis and treatment of the bone diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.